ADMA Biologics, Inc. (ADMA)
9.33
-0.06
(-0.64%)
USD |
NASDAQ |
Sep 01, 16:00
9.34
+0.01
(+0.11%)
After-Hours: 20:00
ADMA Biologics Cash from Investing (Quarterly) : -2.256M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.256M |
| March 31, 2026 | 2.404M |
| December 31, 2025 | -0.276M |
| September 30, 2025 | -14.37M |
| June 30, 2025 | -2.527M |
| March 31, 2025 | -4.72M |
| December 31, 2024 | -2.75M |
| September 30, 2024 | -1.098M |
| June 30, 2024 | -2.365M |
| March 31, 2024 | -2.362M |
| December 31, 2023 | -1.407M |
| September 30, 2023 | -0.7566M |
| June 30, 2023 | -0.8726M |
| March 31, 2023 | -1.945M |
| December 31, 2022 | -3.748M |
| September 30, 2022 | -3.380M |
| June 30, 2022 | -3.940M |
| March 31, 2022 | -2.842M |
| December 31, 2021 | -3.676M |
| September 30, 2021 | -2.789M |
| June 30, 2021 | -4.476M |
| March 31, 2021 | -2.571M |
| December 31, 2020 | -3.598M |
| September 30, 2020 | -2.885M |
| June 30, 2020 | -4.168M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.073M |
| December 31, 2019 | -1.594M |
| September 30, 2019 | -1.972M |
| June 30, 2019 | -0.1352M |
| March 31, 2019 | -0.1105M |
| December 31, 2018 | -0.819M |
| September 30, 2018 | -0.2302M |
| June 30, 2018 | -0.4971M |
| March 31, 2018 | -0.5492M |
| December 31, 2017 | -2.010M |
| September 30, 2017 | -0.5699M |
| June 30, 2017 | 12.65M |
| March 31, 2017 | 5.142M |
| December 31, 2016 | 5.626M |
| September 30, 2016 | 0.2389M |
| June 30, 2016 | -8.617M |
| March 31, 2016 | 3.656M |
| December 31, 2015 | 5.401M |
| September 30, 2015 | 4.157M |
| June 30, 2015 | -4.426M |
| March 31, 2015 | -6.874M |
| December 31, 2014 | 1.111M |
| September 30, 2014 | -1.402M |
| June 30, 2014 | -4.369M |
| March 31, 2014 | 0.6202M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Erasca, Inc. | 19.49M |
| Krystal Biotech, Inc. | -161.58M |
| Vericel Corp. | -2.82M |
| Emergent BioSolutions, Inc. | -52.30M |
| Exelixis, Inc. | 91.43M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 29.54M |
| Cash from Financing (Quarterly) | -29.42M |
| Free Cash Flow | 116.22M |
| Free Cash Flow Per Share (Quarterly) | 0.1184 |
| Free Cash Flow to Equity (Quarterly) | 27.85M |
| Free Cash Flow to Firm (Quarterly) | 29.86M |
| Free Cash Flow Yield | 5.20% |